Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053667 | 0.81 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL10053654 | 0.73 | MAPT (0.39) | CYP2C19 | |
| SCHEMBL10053668 | 0.72 | CYP2C19 (0.41) | CYP2C19 | |
| SCHEMBL10053662 | 0.72 | CYP2C19 (0.33) | CYP2C19 | |
| SCHEMBL13282200 | 0.69 | — | — | |
| SCHEMBL29885245 | 0.65 | — | — | |
| SCHEMBL8339439 | 0.62 | — | — | |
| SCHEMBL14401470 | 0.62 | — | — | |
| SCHEMBL11983065 | 0.62 | — | — | |
| SCHEMBL1659264 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097709-B2 | Macrolactam compounds | Novobiotic Pharmaceuticals, Inc. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097709-B2 | Macrolactam compounds | Novobiotic Pharmaceuticals, Inc. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090156514-A1 | NOVEL MACROLACTAM COMPOUNDS | NOVOBIOTIC PHARMACEUTICALS LLC (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156514-A1 | NOVEL MACROLACTAM COMPOUNDS | NOVOBIOTIC PHARMACEUTICALS LLC (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009026527-A1 | NOVEL MACROLACTAM COMPOUNDS | NOVOBIOTIC PHARMACEUTICALS LLC (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156514-A1 | NOVEL MACROLACTAM COMPOUNDS | MRPS18B, HDAC6, MLST8 | CYP2C19 2476/4885CYP2D6 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.